tradingkey.logo

LivaNova PLC

LIVN

55.000USD

-0.910-1.63%
Close 09/19, 16:00ETQuotes delayed by 15 min
3.00BMarket Cap
LossP/E TTM

LivaNova PLC

55.000

-0.910-1.63%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
27 / 207
Overall Ranking
80 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
63.632
Target Price
+13.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.67% year-on-year.
Fairly Valued
The company’s latest PE is -14.22, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 56.85M shares, decreasing 10.89% quarter-over-quarter.
Held by PRIMECAP Management
Star Investor PRIMECAP Management holds 4.64M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.97, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 352.52M, representing a year-over-year increase of 10.66%, while its net profit experienced a year-over-year increase of 66.30%.

Score

Industry at a Glance

Previous score
8.97
Change
0

Financials

8.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

9.40

Operational Efficiency

9.35

Growth Potential

9.57

Shareholder Returns

7.57

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -14.45, which is -375.90% below the recent high of 39.87 and -116.10% above the recent low of -31.23.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.40, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for LivaNova PLC is 60.00, with a high of 80.00 and a low of 53.32.

Score

Industry at a Glance

Previous score
8.40
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts
Buy
Current Rating
63.632
Target Price
+13.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
LivaNova PLC
LIVN
10
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.18, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 58.94 and the support level at 52.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.18
Change
-0.4

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.322
Neutral
RSI(14)
52.050
Neutral
STOCH(KDJ)(9,3,3)
22.965
Neutral
ATR(14)
1.409
High Vlolatility
CCI(14)
-95.145
Neutral
Williams %R
80.123
Oversold
TRIX(12,20)
0.395
Sell
StochRSI(14)
25.169
Sell
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
55.160
Sell
MA10
56.292
Sell
MA20
56.485
Sell
MA50
50.498
Buy
MA100
47.225
Buy
MA200
45.651
Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 104.11%, representing a quarter-over-quarter increase of 0.28%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.64M shares, representing 8.50% of shares outstanding, with 2.91% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
6.53M
-0.55%
PRIMECAP Management Company
Star Investors
4.61M
-3.06%
The Vanguard Group, Inc.
Star Investors
2.65M
+13.56%
Millennium Management LLC
2.07M
-32.27%
State Street Global Advisors (US)
2.10M
-0.05%
AQR Capital Management, LLC
1.57M
+111.71%
Dimensional Fund Advisors, L.P.
1.33M
+1.60%
Geode Capital Management, L.L.C.
1.41M
+5.53%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.68, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.68
Change
0
Beta vs S&P 500 index
0.97
VaR
+3.18%
240-Day Maximum Drawdown
+37.12%
240-Day Volatility
+39.48%
Return
Best Daily Return
60 days
+11.15%
120 days
+23.72%
5 years
+23.72%
Worst Daily Return
60 days
-5.01%
120 days
-5.11%
5 years
-15.76%
Sharpe Ratio
60 days
+2.42
120 days
+1.63
5 years
+0.20
Risk Assessment
Maximum Drawdown
240 days
+37.12%
3 years
+47.23%
5 years
+63.48%
Return-to-Drawdown Ratio
240 days
+0.11
3 years
+0.11
5 years
-0.01
Skewness
240 days
+2.09
3 years
+1.38
5 years
+0.83
Volatility
Realised Volatility
240 days
+39.48%
5 years
+41.02%
Standardised True Range
240 days
+2.60%
5 years
+3.68%
Downside Risk-Adjusted Return
120 days
+390.04%
240 days
+390.04%
Maximum Daily Upside Volatility
60 days
+32.98%
Maximum Daily Downside Volatility
60 days
+24.88%
Liquidity
Average Turnover Rate
60 days
+1.21%
120 days
+1.35%
5 years
--
Turnover Deviation
20 days
+20.00%
60 days
+4.03%
120 days
+15.65%

Peer Comparison

Healthcare Equipment & Supplies
LivaNova PLC
LivaNova PLC
LIVN
7.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI